Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?

Antiviral Therapy

Volumn 10, Issue 7, 2005, Pages 779-790

  Mocroft, Amanda ^a   Rockstroh, Jurgen ^b   Soriano, Vincent ^c   Ledergerber, Bruno ^d   Kirk, Ole ^e   Vinogradova, Elena ^f   Reiss, Peter ^g   Katlama, Christine ^h   Phillips, Andrew N ^a   Lundgren, Jens D ^e  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e HVIDOVRE HOSPITAL   (Denmark)

^f St Petersburg AIDS Center   (Russian Federation)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; FOLLOW UP; GENDER; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PATIENT; PHYSICIAN; PRIORITY JOURNAL; RISK ASSESSMENT; SEROLOGY; SIDE EFFECT; STATISTICAL MODEL; VIRUS INFECTION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOICE BEHAVIOR; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT REFUSAL;

EID: 27844497009     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Yeni PG, Hammer SM, Hirsch MS, Schechter M, Carpenter CCJ, Fishl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S & Volberding PA. Treatment for adult HIV infection - 2004 recommendations of the international AIDS society - USA panel. Journal of the American Medical Association 2004; 292:251-265.
2. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, Garcia-Viejo MA, Mallolas J, Carne X, Phillips A & Gatell JM. Hepatotoxicity in HIV-1 infected patients receiving nevirapine containing antiretroviral therapy. AIDS 2001; 15:1261-1268.
3. Sulkowski MS, Thomas DL, Chaisson RE & Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of Hepatitis C or B virus infection. Journal of the American Medical Association 2000; 283:74-80.
4. Den Brinker M, de Wit FWNM, Wertheim-van Dillen PME, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ & Lange JM. Hepatitis B and C virus coinfection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14:2895-2902.
5. Sulkowski MS & Thomas DL. Hepatitis C in the HIV-infected person (review). Annals of Internal Medicine 2003; 138:197-207.
6. Cattelan AM, Erne E, Salatino A, Trevenzoli M, Carretta G, Meneghetti F & Cadrobbi P. Severe hepatic failure related to nevirapine treatment. Clinical Infectious Diseases 1999; 29:455-456.
7. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L & Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2001; 27:426-431.
8. Winnock M, Salmon-Ceron D, Dabis F & Chene G. Interactions between HIV-1 and HCV infections: Towards a new entity? Journal of Antimicrobial Chemotherapy 2004; 53:936-956.
9. Greub G, Ledergerber B, Battegay M, Grob B, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti JC, Hirschel B, Janin P, Francioli P, Flepp M & Telenti A. Clinical progression, survival and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort study. Lancet 2000; 356:1800-1805.
10. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral naïve patients: A 3-year randomised trial. JAMA 2004; 292:191-201.
11. Gulick RM, Ribaudo HJ, Shikurma CM, Lustgarten S, Squires KE, Meyer WA 3rd, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL & Kuritzkes DR; AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the intitial treatment of HIV-1 infection. The New England Journal of Medicine 2004; 350:1850-1861.
12. d'Arminio Monforte A, Cozzi Lepri A, Rezza G, Antinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U & Moroni M. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. AIDS 2000; 14:499-507.
13. Ripamonti D, Arici C, Pezzotti P, Maggioli F, Ravasio L & Suter F. Hepatitis C infection raises the risk of the modification of first highly active antiretroviral therapy in HIV-infected patients (letter). AIDS 2004; 18:243-245.
14. Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, Boron-Kaczmarska A, Viksna L, Kirk O & Lundgren JD. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: Increased incidence of stopping due to toxicity or patient/physician choice in patients with Hepatitis C coinfection. AIDS Research and Human Retroviruses 2005; (in press).
15. Rockstroh J, Konopnicki D, Soriano V, Kirk O, Antunes F, Knysz B, Tural C, de Wit S, Mocroft A & Lundgren J. Hepatitis B and Hepatitis C in the EuroSIDA cohort: Prevalence and effect on mortality, AIDS progression and response to HAART. 11th Conference on Retroviruses and Opportunistic Infections. February 8-11, 2004, San Francisco, USA. Abstract 799.
16. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN & Lundgren JD; EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
17. Galli M, Cozzi Lepri Z, Ridolfi AL, Gervasconi C, Ravasio L, Corsico L, Gianelli E, Vaccarezza M, Vullo V, Cargnel A, Minoli L, Coronado O, Giacometti A, Antinori A, Antonucci G, D'Arminio Monforte A & Moroni M; LipoICoNa Study. Incidence of adipose tissue alterations in first-line antiretroviral therapy. The LipoICoNa study. Archives of Internal Medicine 2002; 162:2621-2626.
18. Martinez E, Mocroft A, Garcia-Viejo MA, JB Perez-Cuavas, JL Blanco, J Mallolas, Bianchi L, Conget I, Blanch J, Phillips A & Gatell JM. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study. Lancet 2001; 357:592-598.
19. Bonfanti P, Guliscano C, Ricci E, Timillero L, Valsecchi L, Carradori S, Pusterla L, Fortuna P, Miccolis S, Magnani C, Gabbuti A, Parazzini F, Martinelli C, Faggion I, Landonio S, Quirino T & Vigevani G; Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. Risk factors for lipodystrophy in the CISAI cohort. Biomedicine & Pharmacotherapy 2003; 57:422-427.
20. Mehta S, Moore RD & Graham NMH. Potential factors affecting adherence with HIV therapy (editorial). AIDS 1997; 11:1665-1670.
21. Antoniou T & Tseng AL. Interactions between recreational drugs and antiretroviral agents. The Annals of Pharmacotherapy 2002; 36:1598-1913.
22. Tedaldi EM, Baker RK, Moorman AC, Alzola CF, Fuhrer J, McCabe RE, Wood KC & Holmberg SD; HIV Outpatient Study (HOPS) Investigators. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clinical Infectious Diseases 2003; 36:363-367.
23. Rancinan C, Neau D, Saves M, Lawson-Ayayi S, Bonnet F, Mercie P, Dupon M, Couzigou P, Dabis F & Chene G; Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA). Is hepatitis C virus coinfection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS 2002; 16:1357-1362.
24. Soriano V, Puoti M, Sulkowski M, Mauss S, Cacoub P, Cargnel A, Dieterich D, Hatzakis A, Rockstroh J. Care of patients with hepatitis C and HIV co-infection (editorial review). AIDS 2004; 18:1-12.
25. Kontorinis N & Dieterich D. Hepatotoxicity of antiretroviral drugs. AIDS Reviews 2003; 5:36-43.
26. Van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW & Lange JM; 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and Lamivudine: A randomised open-label trial, the 2 NN study. Lancet 2004; 363:1253-1263.
27. Shafer RW, Smeaton LM, Robbins GK, de Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS & Merigan TC; AIDS Clinical Trials Group 384 Team. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. The New England Journal of Medicine 2003; 349:2304-2315.
28. Lazzarin A, Clotet B, Cooper DA, Reynes J, Arasteh K, Nelson MA, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C & Salgo M; TORO 2 Study Group. Efficacy of enfurvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. The New England Journal of Medicine 2003; 348:2186-2195.
29. Gullick RM, Ribaudo HJ, Shikurma CM, Lustgarten S, Squires KE, Meyer WA 3rd, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL & Kuritzkes DR; AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. The New England Journal of Medicine 2004; 350:1850-1861.
30. Gerstoft J, Kirk O, Obel N, Pedersen C, Mathiesen L, Nielsen H, Katzenstein TL & Lundgren JD. Low efficacy and high frequency of adverse events in a randomised trial of the triple nucleoside regimen abacavir, stavudine and Didanosine. AIDS 2003; 17:2045-2052.
31. Barreiro P, Garcia-Benayas T, Rendon A, Rodriguez-Novoa S & Soriano V. Combinations of nucleoside/nucleotide analogues for HIV therapy. AIDS Reviews 2004; 6:234-243.
32. National Institutes of Health. Consensus Development Conference: Management of Hepatitis C. Final Statement. Gastroenterology 2002; 123:2082-2099.